Skip to main content
Figure 2 | BMC Psychiatry

Figure 2

From: Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

Figure 2

Changes in PANSS Total Scores Over Time (LOCF) in the ITT Analysis Set (p-values for Paliperidone Palmitate vs. Placebo). The administration of paliperidone palmitate 234 mg on Day 1 was associated with a significantly greater improvement than placebo on mean PANSS total score at the Day 8 assessment (LS mean [SE] change from baseline -8.21 [0.87] vs. -5.79 [1.20], p = 0.037). In a dose-dependent fashion, all paliperidone palmitate groups continued to show greater PANSS total score improvement than placebo at subsequent timepoints.

Back to article page